ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

10542	Companies
222635	Keywords
151736	Articles
117796	Press releases

Home
Companies
ABIVAX

BRIEF

published on 06/02/2026 at 10:16, 7 days 14 hours ago

Bank of America Corporation exceeds 5% of ABIVAX's capital

Actions Abivax Financial Market Crossing Thresholds Bank Of America
BRIEF

published on 06/01/2026 at 22:10, 8 days 3 hours ago

Promising results of obefazimod in the treatment of ulcerative colitis

Abivax Obefazimod Ulcerative Colitis Clinical Trial FDA Authorization
BRIEF

published on 06/01/2026 at 22:10, 8 days 3 hours ago

Abivax Announces Phase 3 Trial Results for Ulcerative Colitis Treatment

Abivax Obefazimod Ulcerative Colitis Clinical Trial Phase 3 Results
PRESS RELEASE

published on 06/01/2026 at 22:05, 8 days 3 hours ago

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Abivax announces positive Phase 3 ABTECT maintenance trial results for obefazimod in ulcerative colitis, demonstrating significant efficacy and safety profile. Plans NDA submission to FDA in late 2026

FDA Abivax Obefazimod Ulcerative Colitis Phase 3
BRIEF

published on 05/29/2026 at 18:05, 11 days 7 hours ago

ABIVAX: Update on capital and voting rights

Share Capital Voting Rights Actions AMF Abivax
BRIEF

published on 05/29/2026 at 18:05, 11 days 7 hours ago

ABIVAX: Share Capital and Voting Rights as of April 30, 2026

Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF

published on 05/22/2026 at 22:10, 18 days 3 hours ago

Abivax Reports Q1 2026 Financials and Key Developments in Obefazimod Trials

Financial Results Abivax Obefazimod Ulcerative Colitis Clinical Trials
BRIEF

published on 05/22/2026 at 22:10, 18 days 3 hours ago

Abivax unveils its Q1 2026 results and progress on Study 108

Financial Results Treasury Obefazimod RCH Study 108
PRESS RELEASE

published on 05/22/2026 at 22:05, 18 days 3 hours ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Abivax reports Q1 2026 financial results and interim data from UC Study 108, showing strong clinical remission with obefazimod. Cash position at €491.6M. Updates on upcoming trials and financial highlights

Financial Results Abivax Obefazimod Clinical Trials UC Study 108
BRIEF

published on 05/11/2026 at 22:10, 29 days 3 hours ago

Abivax: Results of the 2026 Annual General Meeting

Biotechnology Abivax Resolutions General Assembly Immune Response

Accesswire

Published on 06/10/2026 at 00:00, 1 hour 12 minutes ago

Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
Published on 06/09/2026 at 23:00, 2 hours 12 minutes ago

NXT Energy Solutions Inc. Announces Results of Annual Meeting of Shareholders
Published on 06/09/2026 at 22:30, 2 hours 42 minutes ago

Gamma Resources Announces Receipt of $604,500 from Warrant Exercises
Published on 06/09/2026 at 21:45, 3 hours 27 minutes ago

Northfield Announces Change of Corporate Name to Juno International Corporation
Published on 06/09/2026 at 15:00, 10 hours 12 minutes ago

Worksport Ltd. Reports Additional $50,000 CEO Insider Stock Acquisition, Reinforcing Confidence in Long-Term Value Creation

View all ACCESSWIRE

EQS Group

Published on 06/09/2026 at 22:55, 2 hours 17 minutes ago

JACOBS STEPS-UP AS 'OFFICIAL SPONSOR OF STAYING AWAKE' AS SCHEDULE REVEALS SUMMER MATCH TIMES WILL PUSH EUROPEAN FOOTBALL FANS TO THE LIMIT
Published on 06/09/2026 at 22:35, 2 hours 37 minutes ago

Eurobattery Minerals publishes Annual Report 2025
Published on 06/09/2026 at 19:32, 5 hours 39 minutes ago

2CRSi SA: 2CRSi announces a €110 million sale of Godì Blackwell Ultra servers in Germany
Published on 06/09/2026 at 19:10, 6 hours 1 minute ago

The 2026 Global Energy Prize shortlist released
Published on 06/09/2026 at 19:10, 6 hours 1 minute ago

THE SULTANATE OF OMAN CONSOLIDATES ITS POSITION AS A STABLE DESTINATION FOR GLOBAL CAPITAL

Les Echos

Published on 06/09/2026 at 19:30, 5 hours 42 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 06/09/2026 at 18:14, 6 hours 58 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2026
Published on 06/09/2026 at 15:17, 9 hours 55 minutes ago

Statement of transactions in own shares from June 1, 2026 to June 5, 2026
Published on 06/09/2026 at 10:37, 14 hours 35 minutes ago

Guillemot Corporation S.A. | Weekly report share buyback from June 1 to June 5 2026
Published on 06/09/2026 at 07:00, 18 hours 12 minutes ago

New strategic Milestone for Biophytis: Official Establishment of Its Joint Venture in Asia

View all LES ECHOS COMFI WIRE